Group 1: Chemical Sector Performance - The chemical raw materials index increased by 1.62%, while the chemical machinery index decreased by 0.96%, the chemical pharmaceuticals index fell by 1.69%, and the pesticide and fertilizer index rose by 4.21% [1] - The top five rising petrochemical products included folic acid up by 20%, battery-grade lithium carbonate up by 11.08%, nitric acid up by 10.43%, sulfur up by 9.95%, and petroleum coke up by 7.23% [1] - The top five declining petrochemical products were liquid chlorine down by 34%, butadiene down by 7.69%, 2,4-D down by 6.09%, trichloroethylene down by 6.00%, and SBS down by 5.90% [1] Group 2: Oil Sector Performance - The oil processing index rose by 1.39%, while the oil extraction index fell by 0.22%, and the oil trading index increased by 3.44% [1] - International crude oil prices continued to decline, with West Texas Intermediate crude oil futures settling at $56.66 per barrel, down 1.36% from December 12, and Brent crude oil futures settling at $60.47 per barrel, down 1.06% from December 12 [1] Group 3: Capital Market Performance of Listed Chemical Companies - The top five rising listed chemical companies included Sulihua Co., Ltd. up by 30.69%, Xinri Hengli up by 27.48%, Reborn Technology up by 23.25%, Ruihua Tai up by 20.93%, and Shenjian Co., Ltd. up by 20.50% [2] - The top five declining listed chemical companies were Huarong Chemical down by 20.01%, Enjie Co., Ltd. down by 18.36%, Weike Technology down by 13.15%, Jinbantai down by 12.83%, and Xingye Co., Ltd. down by 12.63% [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 HS387片是一款由公司自主研发的选择性KIF18A抑制剂，拟用于高级别浆液性卵巢癌、非小细胞肺癌 等晚期实体瘤治疗。该药品已经获得国家药品监督管理局颁发的《药物临床试验批准通知书》，详见公 司于2025年7月2日披露的《关于获得药物临床试验批准通知书的公告》（公告编号：临2025-37号）。 2025年11月，公司完成向美国FDA递交HS387片的临床试验申请，并于近日获得FDA批准。截至目前， 国内外有多款KIF18A抑制剂进入临床研发阶段，目前尚无药物上市。 近日，浙江海正药业股份有限公司（以下简称"公司"）收到美国食品药品监督管理局（以下简称"美国 FDA"）的通知，由公司申报的HS387片药品临床试验申请已获得美国FDA批准，可以在美国开展临床 试验。现就相关情况公告如下： 一、药品基本情况 药品名称：HS387片 IND编号：IND 178632 申请事项：新药临床试验申请 申请人：浙江海正药业股份有限公司 二、该药品研发及相关情况 董事会 二○二五年十二月二十三日 ...

苏州鲲泰生物科技有限公司，成立于2022年，位于苏州市，是一家以从事研究和试验发展为主的企业。 企业注册资本5000万人民币。通过天眼查大数据分析，苏州鲲泰生物科技有限公司参与招投标项目6 次，专利信息4条，此外企业还拥有行政许可4个。 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 国家知识产权局信息显示，苏州富士莱医药股份有限公司；苏州鲲泰生物科技有限公司取得一项名 为"一种L96侧链化合物的制备方法"的专利，授权公告号CN118993970B，申请日期为2023年5月。 天眼查资料显示，苏州富士莱医药股份有限公司，成立于2000年，位于苏州市，是一家以从事化学原料 和化学制品制造业为主的企业。企业注册资本9167万人民币。通过天眼查大数据分析，苏州富士莱医药 股份有限公司共对外投资了4家企业，参与招投标项目57次，财产线索方面有商标信息20条，专利信息 108条，此外企业还拥有行政许可82个。 ...

（记者 胡玲） 东诚药业（002675.SZ）12月23日在投资者互动平台表示，公司目前正在积极推进氟[18F]思睿肽注射液 NDA申报前的准备工作，预计2026年上半年提交NDA，审批时间具有不确定性。公司将根据监管要求 及时履行信息披露义务，请关注后续相关公告。 每经AI快讯，有投资者在投资者互动平台提问：请问该思睿肽注射液目前是否已提交NDA？若尚未提 交，预计提交时间及后续审批周期大概多久，最快何时能上市？ ...

Group 1 - The company has a cultivation license for cannabis in the United States but is not currently engaged in related operations [1] - The U.S. project company is not included in the company's consolidated financial statements [1] - Ongoing litigation regarding a stock buyback dispute is affecting the company's involvement in the U.S. project [1]

Market Overview - The Shanghai Composite Index rose by 0.69% to 3917 points on December 22, with significant gains in the Hainan sector driven by the duty-free concept, while the SPD concept declined, leading to notable losses in the millet economy and banking sectors [1]. High-Performing Stocks - Victory Energy achieved a seven-day consecutive rise, with a price increase of 49.98% to 28.75, attributed to control changes and developments in robotics [3][4]. - Jia Mei Packaging recorded a 10.05% increase, reaching 6.68, benefiting from control changes and its position as a leader in three-piece cans [4]. - Zhuangyuan Pasture and Luyuan Pharmaceutical both saw a 10.04% increase, with prices at 15.02 and 20.09% respectively, driven by the dairy and pet economy [4]. - Changfei Fiber and Shenjian Co. also performed well, with increases of 10% and 10.04% respectively, supported by advancements in optical fiber technology and commercial aerospace [4]. Trading Activity - The top three net buying stocks on the Dragon and Tiger list were Shanzi Gaokao, Haima Automobile, and Shennong Seed Industry, with net purchases of 688 million, 302 million, and 260 million respectively [5][6]. - Conversely, the top three net selling stocks included Wangzi New Materials, Xue Ren Group, and Central Mall, with net sales of 192 million, 111 million, and 88 million respectively [7]. Company Highlights - Snowman Group reported a total revenue of 1.631 billion yuan, a year-on-year increase of 24.26%, and a net profit of 39.17 million yuan, up 16.63%, indicating steady growth in both revenue and profit [19]. - The company is recognized as a leading manufacturer of ice-making systems and is actively expanding into the fuel cell industry, showcasing its diversified technological advantages [19]. - The company has also established a partnership for drug promotion and raw material supply, highlighting its advantages in the industry chain [12]. Stock Performance - Haima Automobile reached a daily limit increase with a turnover rate of 17.18% and a transaction volume of 2.577 billion yuan, with a net purchase of 302 million from the Dragon and Tiger list [20]. - Shenjian Co. also hit the daily limit, with a turnover rate of 31.53% and a transaction volume of 2.225 billion yuan, despite a net sell-off of 40.25 million by institutions [20].

证券日报网讯12月22日，泓博医药（301230）在互动平台回答投资者提问时表示，股价走势受宏观环 境、行业周期及市场情绪等多重因素影响，涨跌属于市场行为。公司目前经营稳定，业务发展持续向 好，公司管理层对公司的未来发展充满信心，并将持续聚焦主营业务，不断提升公司经营质量和盈利能 力，致力于为投资者创造长期、可持续的价值回报。未来如有相关计划，公司将及时履行信息披露义 务。 ...

毕得医药公告称，2025年11月13日至12月19日，股东舟山兰旦企业管理合伙企业（有限合伙）及其一致 行动人吴波、舟山欣曦企业管理合伙企业（有限合伙）合计减持公司股份102.24万股，占总股本 1.12%。本次权益变动后，三者合计持股比例由11.12%降至10%，触及5%整数倍。本次减持系履行此前 计划，不触及要约收购，不会对公司治理及经营产生重大影响，减持计划尚未实施完毕。 ...

浙江医药：股东计划于1月16日至4月15日期间减持不超过公司2%的股份。 ...

Core Viewpoint - Warner Pharmaceuticals (688799) has received approval from the National Medical Products Administration for the registration certificate of Isoproterenol Hydrochloride Injection, which is used for treating cardiogenic or infectious shock, complete atrioventricular block, and cardiac arrest [1] Group 1 - The approval of Isoproterenol Hydrochloride Injection marks a significant milestone for the company in expanding its product offerings in critical care [1] - The drug is indicated for serious medical conditions, potentially increasing its market demand and relevance in emergency medicine [1] - This development may enhance the company's competitive position within the pharmaceutical industry, particularly in the cardiovascular treatment segment [1]